Evidence map›Paper›PMID 36388022›Full record

ArticleTranslational cancer research2022

Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review.

Yiping Feng, Qingsheng Xu, Minwei Fang, Chi Hu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yiping FengDepartment of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Qingsheng XuDepartment of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Minwei Fang *Day Surgery Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Chi Hu *Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diffuse midline glioma with a histone H3-K27M mutation is a brand-new tumor entity according to the 2016 edition of World Health Organization (WHO) classification. As diffuse midline gliomas are aggressive and incurable brain tumors, characterized by high levels of intrinsic and acquired resistance to therapy, as well as conventional treatment can hardly work due to an intact blood-brain barrier, leading to very poor outcomes for patients. Anlotinib is a multitarget tyrosine kinase inhibitor and has been used for the treatment of multiple tumor species, with satisfying outcomes. However, anlotinib has not been reported for the treatment of patients with diffuse midline glioma. Case Description: This is a case report about a 51-year-old man suffering from diffuse midline glioma with a histone H3-K27M mutation. After surgery, the patient underwent chemoradiation treatment and then adjuvant temozolomide (TMZ). After 7 months, the tumor had enlarged with severe peritumor edema and hydrocephalus. Bevacizumab was treated for 3 cycles, and then the treatment was changed to anlotinib combined with TMZ. After 8 months, magnetic resonance imaging (MRI) scans showed that the mass was significantly reduced compared with before targeted therapy. Until the present time, the patient has survived for 20 months. Conclusions: Therapy combining anlotinib with TMZ is potential therapeutic option for the patients with diffuse midline glioma.

Indexed as

Anlotinibcase reportdiffuse midline gliomaH3-K27M mutationtargeted therapy

Identifiers

PMID36388022
PMCPMC9641137
OpenAlexW4295067396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.